These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22728987)

  • 21. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases.
    Shimokawa H
    J Cardiovasc Pharmacol; 2002 Mar; 39(3):319-27. PubMed ID: 11862109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of HA-1077 and Y-27632, two rho-kinase inhibitors, in the human umbilical artery.
    Ark M; Ozveren E; Yazici G; Korkmaz B; Büyükafsar K; Arikan O; Kubat H; Songu-Mize E
    Cell Biochem Biophys; 2004; 41(3):331-42. PubMed ID: 15509884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent progress in the treatment of pulmonary arterial hypertension: expectation for rho-kinase inhibitors.
    Fukumoto Y; Tawara S; Shimokawa H
    Tohoku J Exp Med; 2007 Apr; 211(4):309-20. PubMed ID: 17409670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rho-kinase inhibition ameliorates peritoneal fibrosis and angiogenesis in a rat model of peritoneal sclerosis.
    Washida N; Wakino S; Tonozuka Y; Homma K; Tokuyama H; Hara Y; Hasegawa K; Minakuchi H; Fujimura K; Hosoya K; Hayashi K; Itoh H
    Nephrol Dial Transplant; 2011 Sep; 26(9):2770-9. PubMed ID: 21378147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rho kinase inhibition attenuates LPS-induced renal failure in mice in part by attenuation of NF-kappaB p65 signaling.
    Meyer-Schwesinger C; Dehde S; von Ruffer C; Gatzemeier S; Klug P; Wenzel UO; Stahl RA; Thaiss F; Meyer TN
    Am J Physiol Renal Physiol; 2009 May; 296(5):F1088-99. PubMed ID: 19225047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension.
    Nagaoka T; Fagan KA; Gebb SA; Morris KG; Suzuki T; Shimokawa H; McMurtry IF; Oka M
    Am J Respir Crit Care Med; 2005 Mar; 171(5):494-9. PubMed ID: 15563635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective effect of fasudil, a Rho-kinase inhibitor, on chemokine expression, leukocyte recruitment, and hepatocellular apoptosis in septic liver injury.
    Thorlacius K; Slotta JE; Laschke MW; Wang Y; Menger MD; Jeppsson B; Thorlacius H
    J Leukoc Biol; 2006 May; 79(5):923-31. PubMed ID: 16641138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rho kinase inhibitors prevent endothelium-dependent contractions in the rat aorta.
    Chan CK; Mak JC; Man RY; Vanhoutte PM
    J Pharmacol Exp Ther; 2009 May; 329(2):820-6. PubMed ID: 19193928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of various kinases in muscarinic M3 receptor-mediated contraction of longitudinal muscle of rat colon.
    Anderson CD; Kendig DM; Al-Qudah M; Mahavadi S; Murthy KS; Grider JR
    J Smooth Muscle Res; 2014; 50():103-19. PubMed ID: 25891767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The rho-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34(+) CML progenitor cells.
    Burthem J; Rees-Unwin K; Mottram R; Adams J; Lucas GS; Spooncer E; Whetton AD
    Leukemia; 2007 Aug; 21(8):1708-14. PubMed ID: 17554385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rho-kinase signalling mediates endotoxin hypersensitivity after partial hepatectomy.
    Slotta JE; Laschke MW; Menger MD; Thorlacius H
    Br J Surg; 2008 Aug; 95(8):976-84. PubMed ID: 18563790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of fasudil on hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats.
    Sun XZ; Tian XY; Wang DW; Li J
    Eur Rev Med Pharmacol Sci; 2014; 18(7):959-64. PubMed ID: 24763873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rho kinase mediates right ventricular systolic dysfunction in rats with chronic neonatal pulmonary hypertension.
    Gosal K; Dunlop K; Dhaliwal R; Ivanovska J; Kantores C; Desjardins JF; Connelly KA; McNamara PJ; Jain A; Jankov RP
    Am J Respir Cell Mol Biol; 2015 Jun; 52(6):717-27. PubMed ID: 25337652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of fasudil on pulmonary hypertension in clinical practice.
    Zhang Y; Wu S
    Pulm Pharmacol Ther; 2017 Oct; 46():54-63. PubMed ID: 28782712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension.
    Jasińska-Stroschein M; Owczarek J; Plichta P; Orszulak-Michalak D
    Pharmacology; 2014; 93(3-4):145-50. PubMed ID: 24662671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rho/Rho kinase as a potential target for the treatment of renal disease.
    Wakino S; Kanda T; Hayashi K
    Drug News Perspect; 2005 Dec; 18(10):639-43. PubMed ID: 16491166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of the Rho-ROCK (Rho-associated kinase) signaling pathway in the regulation of pancreatic beta-cell function.
    Hammar E; Tomas A; Bosco D; Halban PA
    Endocrinology; 2009 May; 150(5):2072-9. PubMed ID: 19106222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rho kinase (ROCK) inhibitors and their application to inflammatory disorders.
    LoGrasso PV; Feng Y
    Curr Top Med Chem; 2009; 9(8):704-23. PubMed ID: 19689376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Purification and in vitro activity of Rho-associated kinase.
    Amano M; Fukata Y; Shimokawa H; Kaibuchi K
    Methods Enzymol; 2000; 325():149-55. PubMed ID: 11036600
    [No Abstract]   [Full Text] [Related]  

  • 40. Inhaled Fasudil Lacks Pulmonary Selectivity in Thromboxane-Induced Acute Pulmonary Hypertension in Newborn Lambs.
    Hanson SFL; Terry MH; Moretta DT; Power GG; Wilson SM; Alam F; Ahsan F; Blood AB; Giri PC
    J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):472-480. PubMed ID: 29756460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.